Recent retractions of key Alzheimer's research papers claiming amyloid-β causes memory loss highlight ongoing scientific controversy and fraud allegations. Despite decades of focus on amyloid plaques as Alzheimer's primary driver, drugs targeting this protein have consistently failed in clinical trials. The field is grappling with fundamental questions about the disease's mechanisms and research integrity.
Background
Alzheimer's disease has been primarily associated with amyloid-β protein plaques since their identification in 1984, forming the basis of most drug development efforts. The amyloid hypothesis has dominated Alzheimer's research for decades despite ongoing debates about its complete validity.
- Source
- Ars Technica
- Published
- Apr 15, 2026 at 10:11 PM
- Score
- 7.0 / 10